Cancer Care

 

 
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML
Principal Investigator (?)
Study Number
F13089
Summary
To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients
(60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint
will be overall survival.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Lebanon

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.